Welcome Message from the Chairman
On behalf of the Organizing Committee, it is our great pleasure to warmly invite you to the 8th Asian Conference on Tumor Ablation (ACTA 2022) which is scheduled at Osstem Implant Twin Tower, Seoul, Korea by the Korean Society of Image-guided Tumor Ablation from October 21(Fri) to 23(Sun), 2022.
ACTA is an annual conference for ablation specialists in Asia aimed at updating their knowledge and sharing experiences on all ablation techniques such as radiofrequency, microwave, and cryoablation. It also aims at discussing their indications not only for the liver but also for the lung, thyroid, kidney, bone, soft tissue, and all other organs.
Under the theme of "Beyond Technical Success", participants will have the opportunity to share the latest information and progress on tumor ablation. Your presence and participation will help facilitate lively and enriching discussions around the conference theme, developing professional knowledge exchange, insights, and collaborations, during the three-day conference.
We look forward to welcoming you to this exciting 8th Asian Conference on Tumor Ablation (ACTA 2022) and to meeting all of you in person in October 2022 here in Seoul, Korea.
Jung Hwan Baek, M.D., Ph.D.
Department of Radiology and Research Institute of Radiology,
University of Ulsan College of Medicine, Asan Medical Center
Welcome Message from the Local Chairman
Dear Colleagues and Friends,
It is our great pleasure to warmly invite you to the 8th Asian Conference on Tumor Ablation (ACTA 2022) in Seoul, Korea from October 21 to 23, 2022.
We held the 3rd ACTA in 2016 very successfully, we are delighted to be hosting ACTA2022 this year.
Asia is the birthplace of ablation such as ethanol injection and microwave ablation, and it has been leading the world in terms of techniques and experience. We believe that we have the responsibility of leading the world into a new stage of ablation.
The Organizing Committee is designing the best possible program with high quality scientific program that will provide a great opportunity for all participants to keep up-to-date with the latest research findings. Also we are planning to invite a large number of world-renowned speakers and delegates to share their insights and achievements.
I ask for your interest and participation, and hope that many people will attend ACTA 2022 to share their knowledge of tumor ablation and enjoy delicious Korean food and autumn atmosphere in Korea.
Young Joon Lee, M.D., Ph.D.
Department of Radiology,
The Catholic University of Korea,
Eunpyeong St. Mary's Hospital
Welcome Message from the Co-Chair(Immediate Past Hosting Chair)
It is a great honor for me to be a co-chair of ACTA 2022 SEOUL. At ACTA 2021 TOKYO,
we could not accept guests from overseas. We hope the COVID-19 pandemic will settle down and we can see each other in person at ACTA 2022 SEOUL.
Ablation is curative, minimally invasive, and can easily treat recurrence, and is also more cost-effective. Ablation is expected to play an increasingly important role in the aging society.
Asia is the region with the world’s largest population which has the highest prevalence of liver cancer. For that reason, there is the largest number of doctors who perform ablation procedures which led to the world’s largest market. Asia is the birthplace of ablation such as ethanol injection and microwave ablation, and has been leading the world in terms of technique and experience. We believe that we have the responsibility of leading the world into a new stage of ablation.
We established Japan Academy of Tumor Ablation (JATA) this year. Last year, SURF trial revealed that surgical resection did not have superiority compared with RFA in overall survival or recurrence-free survival. SURF trial was a randomized controlled trial in which 49 major centers in Japan enrolled HCC patients. This year, radiofrequency ablation for lung, renal, and bone and soft tissue tumors will be covered by public health insurance in Japan
We look forward to many more doctors participating in ACTA activities. And I have no doubt that ACTA 2022 SEOUL will be another significant step for the advancement of ablation.
Shuichiro Shiina, M.D., Ph.D.
Co-Chair (Immediate Past Hosting Chair)
Department of Gastroenterology, Juntendo University
Welcome Message from the Co-Chair(President Elect)
It is my greatest honor and pleasure to extend to you all a warm invitation to attend and participate in the 8th Asian Conference on Tumor Ablation (ATCA), which will be held on October 21-23, Seoul, Korea.
Building on the success of previous Conferences, ACTA has become a great international platform for updating and communicating the most novel ideas and experiences on tumor ablation. As a minimally invasive treatment, ablation has been widely used in treating tumor of liver, kidney, lung, etc. With the booming of recent studies revealing the potential synergistic effect of ablation and systematic therapies, the role of tumor ablation has been extended from a curative therapy for small tumor lesions to a promising therapy for advanced tumors. The theme of the 8th ATCA is “Beyond Technical Success”, which I hope may also induce a high-level discussion on the future role of tumor ablation.
I am looking forward to meeting you all in October, and with your cooperation, I have implicit faith that ACTA will continue to be one of the greatest platforms for tumor ablation internationally.
Also, I would like to thank Chairman Jung Hwan Baek, Chairman Young Joon Lee and all the members participating in the organization of this unique event. I sincerely wish this conference great success.
Ming KUANG, M.D., Ph.D.
Co-chair (Elected Hosting Chair)
Center of Hepato-Pancreato-Biliary Surgery,
The First Affiliated Hospital, Sun Yat-sen University